NIRAVAM

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).

How it works

NIRAVAM (alprazolam) is a benzodiazepine that potentiates GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and decreased excitability.

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; major metabolites include alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive), both conjugated and excreted renally.
Excretion	Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Half-life	Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Protein binding	~95% bound, primarily to albumin.
Volume of Distribution	1.5–2.5 L/kg (mean 1.8 L/kg). Indicates extensive tissue distribution including CNS.
Bioavailability	Sublingual: ~75% (avoiding first-pass). Oral: ~50% (due to first-pass metabolism).
Onset of Action	Sublingual: 15–30 minutes (faster absorption vs oral, due to bypass of first-pass metabolism). Oral: 30–60 minutes.
Duration of Action	Sublingual: 4–6 hours (anxiolytic effect). Oral: 6–8 hours. Duration correlates with half-life; shorter than other benzodiazepines.

Classification & Brands

Dosing & administration

0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.

Dosage form	TABLET, ORALLY DISINTEGRATING
Renal impairment	No specific guidelines; use cautiously in severe impairment (CrCl <30 mL/min) due to potential accumulation.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: 0.25 mg every 8–12 hours; Child-Pugh Class C: not recommended.
Pediatric use	Not FDA-approved for pediatric use; no established weight-based dosing.
Geriatric use	Initial dose 0.25 mg sublingually every 8–12 hours; increase cautiously. Avoid use in elderly with hepatic impairment or renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).

Breastfeeding	Enters breast milk (M/P ratio ~0.24). Relative infant dose ~3% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and weight loss. Avoid if infant has apnea or sleep apnea.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: case reports of cleft lip/palate (odds ratio ~2.0). Second and third trimesters: risk of floppy infant syndrome, neonatal withdrawal (hypertonia, tremors, feeding difficulties), and respiratory depression. Use only if benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Risk of serious adverse outcomes from concomitant use with opioid medications, including respiratory depression, profound sedation, coma, and death. Reserve use for patients with inadequate alternative treatment options.

Side Effect Profile

Serious Effects

Absolute Contraindications

Hypersensitivity to alprazolam or other benzodiazepines; concurrent use with ketoconazole or itraconazole (CYP3A4 inhibitors causing elevated alprazolam levels); acute narrow-angle glaucoma; concomitant use with opioid analgesics except under limited circumstances.

Clinical Precautions

Precautions

Risk of abuse, misuse, and addiction; dependence and withdrawal reactions; risk of CNS depression and impaired psychomotor function; caution in patients with hepatic impairment, renal impairment, or respiratory disease; risk of paradoxical reactions; potential for neonatal sedation and withdrawal syndrome when used during pregnancy.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NIRAVAM

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).

How it works

What the body does with it

Metabolism	Primarily hepatic via CYP3A4; major metabolites include alpha-hydroxyalprazolam (active) and 4-hydroxyalprazolam (inactive), both conjugated and excreted renally.
Excretion	Renal: ~90% as metabolites (glucuronide conjugates and oxidized products), <5% unchanged. Fecal: <10%.
Half-life	Terminal elimination half-life: 8–14 hours (mean 10.5 h). Clinically, steady-state reached in ~3 days; accumulation minimal at typical dosing.
Protein binding	~95% bound, primarily to albumin.
Volume of Distribution	1.5–2.5 L/kg (mean 1.8 L/kg). Indicates extensive tissue distribution including CNS.
Bioavailability	Sublingual: ~75% (avoiding first-pass). Oral: ~50% (due to first-pass metabolism).
Onset of Action	Sublingual: 15–30 minutes (faster absorption vs oral, due to bypass of first-pass metabolism). Oral: 30–60 minutes.
Duration of Action	Sublingual: 4–6 hours (anxiolytic effect). Oral: 6–8 hours. Duration correlates with half-life; shorter than other benzodiazepines.

Classification & Brands

Dosing & administration

0.25–0.5 mg sublingually every 6–8 hours as needed; maximum 2 mg/day.

Dosage form	TABLET, ORALLY DISINTEGRATING
Renal impairment	No specific guidelines; use cautiously in severe impairment (CrCl <30 mL/min) due to potential accumulation.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: 0.25 mg every 8–12 hours; Child-Pugh Class C: not recommended.
Pediatric use	Not FDA-approved for pediatric use; no established weight-based dosing.
Geriatric use	Initial dose 0.25 mg sublingually every 8–12 hours; increase cautiously. Avoid use in elderly with hepatic impairment or renal impairment.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NIRAVAM (NIRAVAM).

Breastfeeding	Enters breast milk (M/P ratio ~0.24). Relative infant dose ~3% of maternal weight-adjusted dose. Monitor infant for sedation, poor feeding, and weight loss. Avoid if infant has apnea or sleep apnea.
Teratogenic Risk	FDA Pregnancy Category D. First trimester: case reports of cleft lip/palate (odds ratio ~2.0). Second and third trimesters: risk of floppy infant syndrome, neonatal withdrawal (hypertonia, tremors, feeding difficulties), and respiratory depression. Use only if benefit outweighs risk.
Fetal Monitoring